Experience with pegylated interferon -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients
Krisstina Gowin(University of Arizona), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Casey L. O’Connell(University of Southern California), Björn Andréasson(NU Hospital Group), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), John Camoriano(WinnMed), John Samuelson(Boston University), Tiziano Barbui(University of Bergamo), John Mascarenhas(Tisch Hospital), Catherine Rea(St Thomas' Hospital), Prakash Thapaliya(WinnMed), Jean‐Jacques Kiladjian(Délégation Paris 5), Alwyn Howard Gentry(WinnMed), Deepti Radia(St Thomas' Hospital)
Cited by 85
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k